|
| Author and year | Age (yrs) | Gender | Symptoms and signs | Laboratory tests | Imaging findings (brain MRI) | Treatment | MRI follow-up |
|
| Ehirim et al., 1998 [8] | 13 | Male | Nausea and vomiting since 10 months | TSH 827 mIU/l (range, 0.5–5.0)
FT4 <1 µg/dl (range, 5–12) | Large homogeneously enhancing sellar and suprasellar pituitary mass, abutting the optic chiasm | Levothyroxine | Complete resolution of the pituitary mass one year after the start of thyroxine therapy |
|
| Young et al., 1999 [9] | 14 | Female | Galactorrhea, recurrent mild occipital headaches, and occasional visual disturbance (loss of peripheral vision) since 6 months | Prolactin 58 ng/ml (range, 3–30)
TSH >100 mIU/l (range, 0.55–3.90)
FT4 <2 mcg/dl (range, 4.4–12.2)
TPOAb and TgAb + | Large pituitary mass compatible with a pituitary macroadenoma | Levothyroxine | Complete resolution of the pseudoadenoma (timing not available) |
| 6.75 | Female | Pubic and axillary hair growth since 6 months, impaired statural growth, and excessive weight gain over the previous year | TSH >60 mIU/l (range, 0.46–4.98)
FT4 2.1 mcg/dl (range, 5–12.5) | Sellar/supersellar mass of 17 × 17 mm, consistent with a pituitary adenoma | Levothyroxine | Complete resolution of the mass with normal pituitary and suprasellar anatomy (timing not available) |
|
| Hopper and Albanese, 2005 [10] | 11 | Female | Frontal headaches, lethargy, and dizziness since 2 months | TSH >1500 mIU/l (range, 0.4–4)
FT4 0.3 pmol/l (range, 12–24)
TPOAb 149 IU/ml (range, 0–109) | Greatly enlarged pituitary gland with homogeneous pituitary tissue impinging on the theoptic chiasm consistent with a pituitary macroadenoma | Levothyroxine | Reduction in the size of the pituitary gland to almost normal size, 5 months after presentation and start of treatment |
| Eom et al., 2008 [11] | 9 | Female | Impaired statural growth and excessive weight gain over the previous year | TSH 57.07 mIU/l (range, 0.2–5)
FT4 0.01 ng/dl (range, 0.7–2) | Large intrasellar and suprasellar pituitary mass, homogeneous enhancing, convex upper contour, and a craniocaudal diameter of 20 mm. Upward extension, encroaching of suprasellar cisterna, superiorly displacing the optic chiasm | Levothyroxine | Complete resolution of the pituitary mass and partially empty sella, 4 months after starting the treatment |
|
| Simsek et al., 2009 [12] | 14.5 | Male | Short stature (−3.6 SDS), delayed puberty, headache, easy fatigability, extreme cold intolerance, and chronic constipation | TSH 334 mIU/l (range, 0.5–5)
FT4 5.2 pmol/l (range, 9–26)
TPOAb and TgAb (sublingual thyroid diagnosed on imaging) | Large pituitary mass with homogeneous enhancement, consistent with a pituitary macroadenoma. | Levothyroxine | Complete resolution of the enlarged pituitary, 6 months after levothyroxine replacement |
| 13 | Female | Severe menorrhagia since 6 months, cold intolerance, marked fatigue, sluggishness, and difficulty in school | TSH 232 mIU/l (range, 0.5–5)
FT4 2.7 pmol/l (range, 9–26)
TPOAb 855 IU/ml (range, 0–35)
TgAb 22 IU/ml (range, 0–40) | Homogeneously enhancing enlarged pituitary (height 11 mm) with suprasellar extension | Levothyroxine | Resolution of the pituitary enlargement, 6 months after starting the treatment |
|
| Cekmez et al., 2011 [13] | 12 | Female | Growth retardation and dry and lifeless hair | TSH >150 mIU/ml (range, 0.24–4)
FT4 0.27 ng/dl (range, 0.58–1.64)
TPOAb 31.2 IU/ml (range, 0–60) | Mass of 16 × 12 mm in the anterior lobe of the pituitary gland consistent with a macroadenoma, with slight extension into the right suprasellar cisterns | Levothyroxine | Reduction in the size of the lesion, 3 months after starting the treatment |
|
| Franceschi et al., 2011 [14] | 10 | Male | Occipital headache over the last three months and height growth arrest over the last to 2 years (decline from the 75–90th centile to the 25th) | TSH 589 mU/l (range, 0.20–4.50)
FT4 1.5 pmol/l (range, 12–22) | Pituitary mass isointense to gray matter, extended on the suprasellar cistern with mild compression of the optic chiasm. The pituitary stalk and posterior pituitary dislocated. After gadolinium, homogeneous enhanced | Levothyroxine | Resolution of the mass, 5 months after starting the treatment |
|
| Eklioglu et al., 2013 [15] | 2.75 | Female | Short stature (height −2.85 SDS) | TSH >100 mU/l (range, 0.6–5.5)
FT4 0.62 ng/dl (range, 0.8–2.2) | Mass of 16 × 13 mm with homogeneous enhancement and extension to suprasellar cisterna, reported as macroadenoma | Levothyroxine | The lesion disappeared one year after starting the treatment |
|
